“I’m in oncology because it offers the opportunity to help patients in so many different ways.”
Dr Hsieh Wen-Son
- Mount Elizabeth
Dr Hsieh Wen-Son is specialised in the treatment of various types of cancers and is active in developing novel cancer diagnostics and molecularly targeted anti-cancer treatments. After studying Philosophy and Psychology at Oxford University on a Rhodes Scholarship, Dr Hsieh obtained his medical degree from Johns Hopkins University. After completion of his training in Internal Medicine at Duke University and in Medical Oncology at Johns Hopkins, Dr Hsieh was active in patient care, teaching, and research as a full time faculty member at the Johns Hopkins University School of Medicine with a primary appointment in the division of haematologic malignancies. He remains a part time Assistant Professor at Johns Hopkins University and is a Principal Associate at the Cancer Sciences Institute of Singapore at the National University of Singapore, where he is active in the development of novel tests and treatments to diagnose and treat cancer.
With a research interest in molecularly targeted cancer therapies, immunotherapy and molecular diagnostics, Dr Hsieh has established a number of international studies involving centres in Singapore, Hong Kong, Korea, the Philippines, Myanmar and the United States examining novel treatments and novel diagnostic tests for lymphomas as well as nasopharyngeal and hepatocellular carcinoma. He has also been the principal investigator of more than thirty completed or ongoing clinical trials investigating novel treatments for a variety of cancers. Dr Hsieh has authored over 80 scientific articles, abstracts, and book chapters and has lectured at regional and international medical and scientific conferences. Dr Hsieh is committed to providing evidence-based treatment for current cancer patients as well as to developing more effective cancer treatments.
Dr Hsieh accepts referrals for all cancer types, with a special clinical interest in lymphoma, head and neck and lung cancers as well as hepatobiliary cancers.
Affiliations & Memberships
- Member of American Association of Cancer Research (AACR)
- Part-time Assistant Professor, Johns Hopkins University School of Medicine,
- Principal Associate, Cancer Sciences Institute of Singapore, National University of Singapore
Cytidine Methylation of Regulatory Sequences Near the Pi-Class Glutathione S-Transferase Gene Accompanies Human Prostatic Carcinogenesis. Lee, W.H, Morton, R.A, Epstein, J.I., Brooks, J.D., Campbell, P.A., Bova, G.S., Hsieh, W.S., Isaacs, W.B., and Nelson, W.G. Natl.Acad. Sci. 1994; 91 (24): 11733-11737.
Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer. Hsieh, WS, Soo, RA, Peh, BK, Loh, T, Dong, DF, Soh, D, Wong, LS, Green, SR, Chiao, JT, Cui, CY, Lai, YF, Lee, SC, Mow, B, Soong, R., Salto-Tellez, M, Goh, BC. Clinical Cancer Research 2009; 15(4): 1435-42.
A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Low, SW, Tao, Q*, Ng, KM, Goh, HK, Shu, XS, Ambinder, RF, Srivastava, G, Shamay, M, Chan ATC, Popescu, NC, Hsieh, WS*. Oncogene 2011; 30(16): 1923-1935. *Co-Corresponding Author.
Plasma Epstein-Barr virus DNA as a marker of tumor response in Hodgkin lymphoma. Kanakry, JA, Li, HL, Gellert, LL, Lemas, MV, Hsieh, WS, Hong, FX, Tan, KL, Gascoyne, RD, Gordon, LI, Fisher, RI, Bartlett, NL, Stiff, P, Cheson, BD, Advani, R, Miller, TP, Kahl, BS, Horning, SJ, Ambinder, RF. Blood 2013; 121 (18): 3547-3553.
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, Rau KM, Poon RT, Yeo WM, Park JW, Tay MH, Hsieh WS, Kappeler C, Rajagopalan P, Krissel H, Jeffers M, Yen CJ, Tak WY. Clinical Cancer Research 2014; 20 (23): 5976-5985.